LINKÖPING, Sweden, December 4, 2025 – AMRA Medical, the global leader in MRI-based fat distribution and muscle composition analytics, is excited to…
Medical Research
The Great Debate: Discussing The Effect of GLP-1-Based Interventions on Muscle at ESC Congress 2025
AMRA’s Dr. Jennifer Linge will serve as a panelist during a session set as a debate on the potential negative effects of GLP-1-based treatments on muscle in individuals with cardiometabolic diseases at the European Society of Cardiology’s 2025 Meeting.
AMRA Headlines as Lead Partner @ The 3rd Annual Obesity and Weight Loss Drug Development Summit!
📅 SAVE THE DATE: July 14th – 16th, 2025 | Boston, MA LINKÖPING, Sweden, July 3, 2025 – We are absolutely thrilled to join…
AMRA Shares Latest Findings at the FSHD Society’s 2025 International Research Congress
LINKÖPING, Sweden, June 19, 2025 AMRA Medical was thrilled to attend the 2025 International Research Congress, hosted by the FSHD Society! The conference,…
New study shows that six out of ten patients with type 2 diabetes (T2D) had metabolic dysfunction-associated steatotic liver disease (MASLD)
LINKÖPING, Sweden, June 17, 2025 – A newly-published study, led by Mattias Ekstedt’s ectopic fat study group at the Department of Health, Medicine…
Latest Data from SURPASS-3 Trial Gleans Insight Into the Association of Tirzepatide Treatment with Changes in Muscle Composition in Type 2 Diabetes
A recent post-hoc analysis of Lilly’s SURPASS-3 trial unravels the impact of tirzepatide treatment on muscle volume and fat infiltration in individuals with Type 2 Diabetes